Free Trial
NASDAQ:CRVS

Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis

Corvus Pharmaceuticals logo
$7.19 +0.15 (+2.13%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$6.98 -0.22 (-2.99%)
As of 10/3/2025 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)

Advanced

Key Stats

Today's Range
$6.76
$7.39
50-Day Range
$4.10
$7.39
52-Week Range
$2.54
$10.00
Volume
1.35 million shs
Average Volume
761,434 shs
Market Capitalization
$535.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Moderate Buy

Company Overview

Corvus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

CRVS MarketRank™: 

Corvus Pharmaceuticals scored higher than 29% of companies evaluated by MarketBeat, and ranked 796th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Corvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Corvus Pharmaceuticals has a consensus price target of $13.00, representing about 80.8% upside from its current price of $7.19.

  • Amount of Analyst Coverage

    Corvus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Corvus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.63) to ($0.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Corvus Pharmaceuticals is -7.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Corvus Pharmaceuticals is -7.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Corvus Pharmaceuticals has a P/B Ratio of 14.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Corvus Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.98% of the outstanding shares of Corvus Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Corvus Pharmaceuticals has recently increased by 0.83%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Corvus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Corvus Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.98% of the outstanding shares of Corvus Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Corvus Pharmaceuticals has recently increased by 0.83%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Corvus Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for CRVS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    28.50% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Corvus Pharmaceuticals' insider trading history.
Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CRVS Stock News Headlines

Corvus Pharmaceuticals Appoints David Moore to Board of Directors
Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
Corvus Pharmaceuticals Appoints David Moore to Board of Directors
See More Headlines

CRVS Stock Analysis - Frequently Asked Questions

Corvus Pharmaceuticals' stock was trading at $5.35 at the start of the year. Since then, CRVS shares have increased by 34.4% and is now trading at $7.19.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) posted its quarterly earnings results on Thursday, August, 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03.
Read the conference call transcript
.

Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), ADMA Biologics (ADMA), Rockwell Medical (RMTI), Axcelis Technologies (ACLS) and Protagonist Therapeutics (PTGX).

Company Calendar

Last Earnings
8/07/2025
Today
10/05/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRVS
CIK
1626971
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$17.00
Low Price Target
$11.00
Potential Upside/Downside
+80.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$62.29 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-28.61%
Return on Assets
-18.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.91
Quick Ratio
8.91

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
14.10

Miscellaneous

Outstanding Shares
74,510,000
Free Float
53,278,000
Market Cap
$535.73 million
Optionable
Optionable
Beta
0.57

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:CRVS) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners